Skip to main content
SpringerLink
Log in

Efficacy and Safety of Insulin Glargine Compared to Other Interventions in Younger and Older Adults: A Pooled Analysis of Nine Open-Label, Randomized Controlled Trials in Patients with Type 2 Diabetes

  • Original Research Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Objective

Elderly patients with type 2 diabetes mellitus (T2DM) present therapeutic challenges related to co-morbidities, treatment adherence, and safety. This study examines the efficacy and safety of insulin glargine compared to other glucose-lowering interventions in younger and older adults.

Methods

In this pooled analysis of 24-week data from nine prospective open-label, multicenter, phase 3/4, two-arm, parallel-group, randomized controlled trials, patients with T2DM aged 18–80 years received insulin glargine (used as a basal insulin regimen) or comparators (including rosiglitazone, pioglitazone, insulin lispro, insulin lispro 75/25, NPH insulin, NPH insulin 30/70, and lifestyle/dietary measures). Endpoints included change from baseline to week 24 in: glycated hemoglobin; fasting plasma glucose; body weight; body mass index; insulin dose; incidence of nocturnal, daytime, or any hypoglycemia. Results were stratified by age (<65, ≥65, 65–74, and ≥75 years) and treatment (insulin glargine or comparator).

Results

A total of 2,938 patients were included (2,263 aged <65 years, 675 aged ≥65 years). Similar levels of glycemic control were achieved in both younger (<65 years) and older (≥65 years) patients with T2DM. Insulin glargine was associated with better glycemic control and a reduced incidence of daytime and any hypoglycemia versus comparator interventions in both younger and older T2DM patients.

Conclusion

This analysis suggests that insulin glargine may represent a safe option to improve glycemic control in older patients with T2DM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. American Diabetes Association. Standards of medical care in diabetes—2012. Diabetes Care. 2012;35(Suppl 1):S11–63.

    Google Scholar 

  2. Resnick HE, Heineman J, Stone R, et al. Diabetes in US nursing homes, 2004. Diabetes Care. 2008;31:287–8.

    Article  PubMed  Google Scholar 

  3. Russell LB, Valiyeva E, Roman SH, et al. Hospitalizations, nursing home admissions, and deaths attributable to diabetes. Diabetes Care. 2005;28:1611–7.

    Article  PubMed  Google Scholar 

  4. Suh D-C, Kim C-M, Choi I-S, et al. Comorbid conditions and glycemic control in elderly patients with type 2 diabetes mellitus, 1988 to 1994 to 1999 to 2004. J Am Geriatr Soc. 2008;56:484–92.

    Article  PubMed  Google Scholar 

  5. Travis SS, Buchanan RJ, Wang S, et al. Analyses of nursing home residents with diabetes at admission. J Am Med Dir Assoc. 2004;5:320–7.

    Article  PubMed  Google Scholar 

  6. Fravel MA, McDanel DL, Ross MB, et al. Special considerations for treatment of type 2 diabetes mellitus in the elderly. Am J Health Syst Pharm. 2011;68:500–9.

    Article  PubMed  CAS  Google Scholar 

  7. Grossman S. Management of type 2 diabetes mellitus in the elderly: role of the pharmacist in a multidisciplinary health care team. J Multidiscip Healthc. 2011;4:149–54.

    Article  PubMed  Google Scholar 

  8. Amiel SA, Dixon T, Mann R, et al. Hypoglycaemia in type 2 diabetes. Diabet Med. 2008;25:245–54.

    Article  PubMed  CAS  Google Scholar 

  9. Chelliah A, Burge MR. Hypoglycaemia in elderly patients with diabetes mellitus: causes and strategies for prevention. Drugs Aging. 2004;21:511–30.

    Article  PubMed  CAS  Google Scholar 

  10. Davies M, Storms F, Shutler S, et al. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care. 2005;28:1282–8.

    Article  PubMed  CAS  Google Scholar 

  11. Haas LB. Optimizing insulin use in type 2 diabetes: role of basal and prandial insulin in long-term care facilities. J Am Med Dir Assoc. 2007;8:502–10.

    Article  PubMed  Google Scholar 

  12. Raskin P, Gylvin T, Weng W, et al. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled study in patients with type 2 diabetes. Diabetes Metab Res Rev. 2009;25:542–8.

    Article  PubMed  CAS  Google Scholar 

  13. Pandya N, DiGenio A, Patel M. Insulin glargine vs comparators in adults <65 vs ≥65 years of age. Diabetes. 2011;60(Suppl. 1):A610.

    Google Scholar 

  14. Patel M, DiGenio A, Pandya N. Pooled analysis reveals greater glycemic control with insulin glargine vs comparators in adults aged 65–74 and ≥75 years. Diabetes 2011;60(Suppl. 1):A617.

    Google Scholar 

  15. Rosenstock J, Sugimoto D, Strange P, et al. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care. 2006;29:554–9.

    Article  PubMed  CAS  Google Scholar 

  16. Gerstein HC, Yale JF, Harris SB, et al. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med. 2006;23:736–42.

    Article  PubMed  CAS  Google Scholar 

  17. Bretzel RG, Nuber U, Landgraf W, et al. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet. 2008;371:1073–84.

    Article  PubMed  CAS  Google Scholar 

  18. Janka HU, Plewe G, Riddle MC, et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care. 2005;28:254–9.

    Article  PubMed  CAS  Google Scholar 

  19. Riddle MC, Rosenstock J, Gerich J. Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080–6.

    Article  PubMed  CAS  Google Scholar 

  20. Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia. 2006;49:442–51.

    Article  PubMed  Google Scholar 

  21. Meneghini LF, Traylor L, Schwartz SL. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus. Endocr Pract. 2010;16:588–99.

    Article  PubMed  Google Scholar 

  22. Blicklé J-F, Hancu N, Piletic M, et al. Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7–8% A1c levels; the TULIP study. Diabetes Obes Metab. 2009;11:379–86.

    Article  PubMed  Google Scholar 

  23. California Healthcare Foundation/American Geriatrics Society Panel on Improving Care for Elders with Diabetes. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc. 2003;51(5 Suppl Guidelines):S265–80.

    Google Scholar 

  24. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–39.

    Article  PubMed  CAS  Google Scholar 

  25. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.

    Article  PubMed  CAS  Google Scholar 

  26. ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.

    Google Scholar 

  27. Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373:1765–72.

    Google Scholar 

  28. Currie CJ, Peter JR, Tynan A, et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet. 2010;375:481–9.

    Article  PubMed  CAS  Google Scholar 

  29. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577–96.

    Google Scholar 

  30. Davis KL, Wei W, Meyers J, et al. A retrospective study of basal insulin analogs in elderly nursing home residents with type-2 diabetes. J Am Geriatr Soc. 2012;60 (Suppl S4):S51.

    Google Scholar 

  31. Alam T, Weintraub N, Weinreb J. What is the proper use of hemoglobin monitoring in the elderly? J Am Med Dir Assoc. 2005;6:200–4.

    Article  PubMed  Google Scholar 

  32. Akram K, Pedersen-Bjergaard U, Borch-Johnsen K, et al. Frequency and risk factors of severe hypoglycemia in insulin-treated type 2 diabetes: a literature survey. J Diabetes Complicat. 2006;20:402–8.

    Article  PubMed  Google Scholar 

  33. Miller ME, Bonds DE, Gerstein HC, et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ. 2010;340:b5444.

    Google Scholar 

  34. Schultes B, Baron M, Bremer JP, et al. Reduced awareness of hypoglycaemia in elderly patients with type 2 diabetes. Diabetes. 2005;54(Suppl 1):Abstract 2222-PO.

    Google Scholar 

  35. Chaudhry SI, Berlowitz DR, Concato J. Do age and comorbidity affect intensity of pharmacological therapy for poorly controlled diabetes mellitus? J Am Geriatr Soc. 2005;53:1214–6.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Funding This study was funded by Sanofi US, Inc. The authors received writing/editorial support in the preparation of this manuscript provided by Pim Dekker, PhD, of Excerpta Medica, funded by Sanofi US, Inc.

Sponsor’s role

This study was funded by Sanofi US, Inc., and was a pooled analysis of data from randomized controlled trials (13–20, Data on file, HOE-901-4021). The writing/editorial support received by the authors in the preparation of this manuscript was funded by Sanofi US, Inc.

Conflict of interest

Pandya: speaker for Sanofi US, Inc. and Novo Nordisk, received consultation fees from Sanofi. DiGenio: employee of Sanofi US, Inc. Gao: Senior statistical consultant for Sanofi US Inc., Analystat Inc. Patel: speaker for Sanofi US, Inc., received research grant from Takeda.

Author contributions

Pandya: Provided clinical expertise in the interpretation of the data and its clinical relevance, critically revised the manuscript outline and draft, provided comments and provided final approval of the manuscript.

DiGenio: Proposed and developed the concept, interpreted the results of the analyses, critically revised the manuscript outline and draft, provided comments and provided final approval of the manuscript.

Gao: Collected the data, developed the analysis plan, conducted statistical analysis and prepared tables with results, critically revised the manuscript outline and draft, provided comments and provided final approval of the manuscript.

Patel: Provided clinical expertise in the interpretation of the data and its clinical relevance, critically revised the manuscript outline and draft, provided comments and provided final approval of the manuscript.

Author information

Authors and Affiliations

  1. Nova Southeastern University College of Osteopathic Medicine, Fort Lauderdale, 3200 S University Dr, Terry Building, Rm 1473, Davie, FL, 33328, USA

    Naushira Pandya

  2. Sanofi US, Inc., Bridgewater, NJ, USA

    Andres DiGenio

  3. Analystat Inc., Belle Mead, NJ, USA

    Ling Gao

  4. Boonshoft School of Medicine, Wright State University, Dayton, OH, USA

    Meenakshi Patel

Authors
  1. Naushira Pandya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andres DiGenio
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ling Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Meenakshi Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Naushira Pandya.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pandya, N., DiGenio, A., Gao, L. et al. Efficacy and Safety of Insulin Glargine Compared to Other Interventions in Younger and Older Adults: A Pooled Analysis of Nine Open-Label, Randomized Controlled Trials in Patients with Type 2 Diabetes. Drugs Aging 30, 429–438 (2013). https://doi.org/10.1007/s40266-013-0069-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-013-0069-9

Keywords

Search

Navigation